Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| iTeos Therapeutics Inc. | Belrestotug (EOS-448/GSK4428859A) - (GALAXIES H&N-202) | PD-L1 positive recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| iTeos Therapeutics Inc. | Inupadenant (EOS-850) - (A2A-005) | metastatic non-squamous non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Oral | Oncology |
| iTeos Therapeutics Inc. | Belrestotug (EOS-448/GSK4428859A) - (GALAXIES Lung-201) | 1L non-small cell lung cancer (NSCLC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Iterum Therapeutics plc | Sulopenem | Complicated intra-abdominal infections (cIAI) | Phase 3 | Trial Discontinued | Oral and intravenous | Antibiotic |
| Iterum Therapeutics plc | Sulopenem | Complicated urinary tract infections (cUTI) | Phase 3 | Trial Discontinued | Oral and intravenous | N/A |
| Jade Biosciences Inc. | AV-101 - (IMPAHCT) | Pulmonary arterial hypertension (PAH) | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Jaguar Health Inc. | Canalevia-CA2 | Chemotherapy-induced diarrhea (CID) in dogs | PDUFA | Ongoing | Oral | Gastroenterology |
| Jaguar Health Inc. | Mytesi (crofelemer) - (OnTarget) | Cancer Therapy-Related Diarrhea | Phase 3 | Trial Completed | oral | Oncology |
